Social withdrawal as a trans-diagnostic predictor of short-term remission: a meta-analysis of five clinical cohorts.
Journal
International clinical psychopharmacology
ISSN: 1473-5857
Titre abrégé: Int Clin Psychopharmacol
Pays: England
ID NLM: 8609061
Informations de publication
Date de publication:
01 03 2022
01 03 2022
Historique:
pubmed:
3
12
2021
medline:
11
3
2022
entrez:
2
12
2021
Statut:
ppublish
Résumé
Social withdrawal is an early manifestation of several neuropsychiatric disorders, and it is characterised by a gradual disengagement from social interactions, potentially leading to complete isolation. This study investigated the association between social withdrawal at baseline and short-term symptom remission in five independent cohorts, including patients with major depressive disorder (MDD), bipolar spectrum disorders, and schizophrenia. Measures of social withdrawal were derived in each study, and clinical remission was estimated based on the psychopathological severity assessed after short-term psychopharmacological treatment (12 weeks). Logistic regression was performed in each sample, adjusting for age and baseline psychopathological severity residualised for social withdrawal. Results were then meta-analysed across samples within a random-effect framework. A total of 4461 patients were included in the analyses (3195 patients with MDD, 655 with bipolar spectrum disorders and 611 with schizophrenia). The meta-analysis showed that higher baseline levels of social withdrawal were associated with a decreased likelihood of short-term remission (ORadj = 0.67, 95% CI, 0.58-0.79, P = 5.28 × 10-7), with the strongest effect in patients with schizophrenia. Overall, our study highlighted the need to address social withdrawal in the early phases of the disease to promote symptom remission in patients with major psychiatric disorders. Understanding the neurobiology underlying social withdrawal may aid the development of medications that can specifically reverse social impairment, thereby fostering clinical remission.
Identifiants
pubmed: 34855649
doi: 10.1097/YIC.0000000000000384
pii: 00004850-202203000-00002
doi:
Banques de données
ClinicalTrials.gov
['NCT00021528']
Types de publication
Journal Article
Meta-Analysis
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
38-45Subventions
Organisme : NIMH NIH HHS
ID : N01MH90003
Pays : United States
Organisme : NIMH NIH HHS
ID : N01 MH90001
Pays : United States
Organisme : NIDA NIH HHS
ID : N01MH80011
Pays : United States
Informations de copyright
Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc.
Références
Addington J, Addington D. (2008) Social and cognitive functioning in psychosis Schizophr Res 99:176–81.
Aleman A, Lincoln TM, Bruggeman R, Melle I, Arends J, Arango C, Knegtering H. (2017). Treatment of negative symptoms: where do we stand, and where do we go? Schizophr Res 186:55–62.
Arango C, Buchanan RW, Kirkpatrick B, Carpenter WT. (2004) The deficit syndrome in schizophrenia: implications for the treatment of negative symptoms Eur Psychiatry 19:21–26.
Bellack AS, Schooler NR, Marder SR, Kane JM, Brown CH, Yang Y. (2004). Do clozapine and risperidone affect social competence and problem solving? Am J Psychiatry 161:364–367.
Bralten J, Mota NR, Klemann C, De Witte W, Laing E, Collier DA, et al. (2021) Genetic underpinnings of sociability in the general population Neuropsychopharmacology 461627–1634.
Briley M, Moret C. (2010) Improvement of social adaptation in depression with serotonin and norepinephrine reuptake inhibitors Neuropsychiatr Dis Treat 6:647–55.
Bukh JD, Andersen PK, Kessing LV (2016). Rates and predictors of remission, recurrence and conversion to bipolar disorder after the first lifetime episode of depression – a prospective 5-year follow-up study. Psychol Med 46:1151–1161.
Cacioppo JT, Cacioppo S, Dulawa S, Palmer AA. (2014) Social neuroscience and its potential contribution to psychiatry World Psychiatry 13:131–139.
Cacioppo S, Grippo AJ, London S, Goossens L, Cacioppo JT. (2015) Loneliness: clinical import and interventions Perspect Psychol Sci 10:238–249.
Chae WR, Nagel JM, Kuehl LK, Gold SM, Wingenfeld K, Otte C. (2019) Predictors of response and remission in a naturalistic inpatient sample undergoing multimodal treatment for depression J Affect Disord 252:99–106.
Corponi F, Fabbri C, Bitter I, Montgomery S, Vieta E, Kasper S, et al. (2019). Novel antipsychotics specificity profile: a clinically oriented review of lurasidone, brexpiprazole, cariprazine and lumateperone. Eur Neuropsychopharmacol 29:971–985.
Cotter J, Granger K, Backx R, Hobbs M, Looi CY, Barnett JH. (2018) Social cognitive dysfunction as a clinical marker: a systematic review of meta-analyses across 30 clinical conditions Neurosci Biobehav Rev, 84:92–99.
De Silva MJ, Cooper S, Li HL, Lund C, Patel V (2013). Effect of psychosocial interventions on social functioning in depression and schizophrenia: meta-analysis. Br J Psychiatry 202:253–260.
Dold M, Bartova L, Fugger G, Kautzky A, Souery D, Mendlewicz J, et al. (2018) Major depression and the degree of suicidality: results of the European Group for the Study of Resistant Depression (GSRD) Int J Neuropsychopharmacol 21:539–549.
Dominguez MD, Saka MC, Lieb R, Wittchen HU, van Os J. (2010) Early expression of negative/disorganized symptoms predicting psychotic experiences and subsequent clinical psychosis: a 10-year study Am J Psychiatry 167:1075–82.
Earley W, Guo H, Daniel D, Nasrallah H, Durgam S, Zhong Y, et al. (2019) Efficacy of cariprazine on negative symptoms in patients with acute schizophrenia: a post hoc analysis of pooled data Schizophr Res 204:282–288.
Eisenberger NI, Cole SW (2012). Social neuroscience and health: neurophysiological mechanisms linking social ties with physical health. Nat Neurosci 15:669–674.
Feldman H, Scheltens P, Scarpini E, Hermann N, Mesenbrink P, Mancione L, et al. (2004) Behavioral symptoms in mild cognitive impairment Neurology 62:1199–1201.
Fett AK, Viechtbauer W, Dominguez MD, Penn DL, van Os J, Krabbendam L. (2011) The relationship between neurocognition and social cognition with functional outcomes in schizophrenia: a meta-analysis Neurosci Biobehav Rev 35:573–88.
Fitzgerald PB, Williams CL, Corteling N, Filia SL, Brewer K, Adams A, et al. (2001) Subject and observer-rated quality of life in schizophrenia Acta Psychiatr Scand 103:387–92.
Green MF, Horan WP, Lee J. (2015) Social cognition in schizophrenia Nat Rev Neurosci 16:620–631.
Gur RC, Gur RE. (2016) Social cognition as an RDoC domain Am J Med Genet B Neuropsychiatr Genet 171B:132–141.
Haro JM, Reed C, Gonzalez-Pinto A, Novick D, Bertsch J, Vieta E, et al. (2011) 2-Year course of bipolar disorder type I patients in outpatient care: factors associated with remission and functional recovery Eur Neuropsychopharmacol 21:287–293.
Heinrichs DW, Hanlon TE, Carpenter WT Jr. (1984). The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome. Schizophr Bull 10:388–398.
Heinssen RK, Liberman RP, Kopelowicz A. (2000) Psychosocial skills training for schizophrenia: lessons from the laboratory Schizophr Bull 26:21–46.
Higgins JP, Thompson SG, Deeks JJ, Altman DG. (2003) Measuring inconsistency in meta-analyses BMJ 327:557–560.
Hirschfeld RM, Montgomery SA, Keller MB, Kasper S, Schatzberg AF, Moller HJ, et al. (2000) Social functioning in depression: a review J Clin Psychiatry 61:268–275.
Holt-Lunstad J, Smith TB, Layton JB. (2010) Social relationships and mortality risk: a meta-analytic review PLoS Med 7:e1000316.
Howland RH. (2008) Sequenced Treatment Alternatives to Relieve Depression (STAR*D). Part 1: study design J Psychosoc Nurs Ment Health Serv 46:21–24.
Hudson JL, Rapee RM. (2000) The origins of social phobia Behav Modif 24:102–29.
IBM (2016) IBM SPSS Advanced Statistics 24 IBM-Nachr.
Kas MJ, Penninx B, Sommer B, Serretti A, Arango C, Marston H. (2019) A quantitative approach to neuropsychiatry: the why and the how Neurosci Biobehav Rev 97:3–9.
Kay SR, Fiszbein A, Opler LA. (1987) The Positive and Negative Syndrome Scale (PANSS) for schizophrenia Schizophr Bull 13:261–276.
Keller M (2001). Role of serotonin and noradrenaline in social dysfunction: a review of data on reboxetine and the Social Adaptation Self-evaluation Scale (SASS). Gen Hosp Psychiatry 23:15–19.
Kelly KM, Mezuk B. (2017) Predictors of remission from generalized anxiety disorder and major depressive disorder J Affect Disord 208:467–474.
Kupferberg A, Bicks L, Hasler G. (2016) Social functioning in major depressive disorder Neurosci Biobehav Rev 69:313–332.
Lambert M, Karow A, Leucht S, Schimmelmann BG, Naber D. (2010) Remission in schizophrenia: validity, frequency, predictors, and patients’ perspective 5 years later Dialogues Clin Neurosci 12:393–407.
Langan D, Higgins JPT, Jackson D, Bowden J, Veroniki AA, Kontopantelis E, et al. (2019) A comparison of heterogeneity variance estimators in simulated random-effects meta-analyses Res Synth Methods 10:83–98.
Leon AC, Solomon DA, Mueller TI, Turvey CL, Endicott J, Keller MB (1999). The Range of Impaired Functioning Tool (LIFE-RIFT): a brief measure of functional impairment. Psychol Med 29:869–878.
Montgomery SA, Asberg M. (1979) A new depression scale designed to be sensitive to change Br J Psychiatry 134:382–389.
Mundt JC, Marks IM, Shear MK, Greist JH (2002). The Work and Social Adjustment Scale: a simple measure of impairment in functioning. Br J Psychiatry 180:461–464.
Novick D, Hong J, Montgomery W, Duenas H, Gado M, Haro JM. (2015) Predictors of remission in the treatment of major depressive disorder: real-world evidence from a 6-month prospective observational study Neuropsychiatr Dis Treat 11:197–205.
Opler MG, Yang LH, Caleo S, Alberti P. (2007) Statistical validation of the criteria for symptom remission in schizophrenia: preliminary findings BMC Psychiatry 7:35.
Paule RC, Mandel J. (1982) Consensus values and weighting factors J Res Natl Bur Stand (1977) 87:377–385.
Porcelli S, Kasper S, Zohar J, Souery D, Montgomery S, Ferentinos P, et al. (2020) Social dysfunction in mood disorders and schizophrenia: clinical modulators in four independent samples Prog Neuropsychopharmacol Biol Psychiatry 99:109835.
Porcelli S, Van Der Wee N, van der Werff S, Aghajani M, Glennon JC, van Heukelum S, et al. (2019) Social brain, social dysfunction and social withdrawal Neurosci Biobehav Rev, 97:10–33.
Rabinowitz J, Levine SZ, Garibaldi G, Bugarski-Kirola D, Berardo CG, Kapur S. (2012) Negative symptoms have greater impact on functioning than positive symptoms in schizophrenia: analysis of CATIE data Schizophr Res 137:147–150.
Reeb-Sutherland BC, Levitt P, Fox NA. (2012) The predictive nature of individual differences in early associative learning and emerging social behavior PLoS One 7:e30511.
Reichman WE, Negron A. (2001) Negative symptoms in the elderly patient with dementia Int J Geriatr Psychiatry, 16(Suppl 1):S7–11.
Rush AJ, Trivedi MH, Stewart JW, Nierenberg AA, Fava M, Kurian BT, et al. (2011) Combining Medications to Enhance Depression Outcomes (CO-MED): acute and long-term outcomes of a single-blind randomized study Am J Psychiatry 168:689–701.
Sachs GS, Thase ME, Otto MW, Bauer M, Miklowitz D, Wisniewski SR, et al. (2003) Rationale, design, and methods of the systematic treatment enhancement program for bipolar disorder (STEP-BD) Biological Psychiatry. 53:1028–1042.
Saris IMJ, Aghajani M, Reus LM, Visser PJ, Pijnenburg Y, van der Wee NJA, et al. (2021) Social dysfunction is transdiagnostically associated with default mode network dysconnectivity in schizophrenia and Alzheimer’s disease. World J Biol Psychiatry 1–14.
Schennach-Wolff R, Jäger M, Mayr A, Meyer S, Kühn KU, Klingberg S, et al. (2011). Predictors of response and remission in the acute treatment of first-episode schizophrenia patients – is it all about early response? Eur Neuropsychopharmacol 21:370–378.
Stroup TS, McEvoy JP, Swartz MS, Byerly MJ, Glick ID, Canive JM, et al. (2003). The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development Schizophr Bull 29:15–31.
Swartz MS, Perkins DO, Stroup TS, McEvoy JP, Nieri JM, Haak DC. (2003) Assessing clinical and functional outcomes in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial Schizophr Bull, 29:33–43.
Teo AR, Lerrigo R, Rogers MA. (2013) The role of social isolation in social anxiety disorder: a systematic review and meta-analysis J Anxiety Disord 27:353–64.
Trivedi MH, Rush AJ, Ibrahim HM, Carmody TJ, Biggs MM, Suppes T, et al. (2004) The Inventory of Depressive Symptomatology, Clinician Rating (IDS-C) and Self-Report (IDS-SR), and the Quick Inventory of Depressive Symptomatology, Clinician Rating (QIDS-C) and Self-Report (QIDS-SR) in public sector patients with mood disorders: a psychometric evaluation Psychol Med 34:73–82.
Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, et al. (2006) Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice Am J Psychiatry 163:28–40.
van der Wee NJA, Bilderbeck AC, Cabello M, Ayuso-Mateos JL, Saris IMJ, Giltay EJ, et al. (2019). Working definitions, subjective and objective assessments and experimental paradigms in a study exploring social withdrawal in schizophrenia and Alzheimer’s disease. Neurosci Biobehav Rev 97:38–46.
Van Rheenen TE, Rossell SL. (2014) Objective and subjective psychosocial functioning in bipolar disorder: an investigation of the relative importance of neurocognition, social cognition and emotion regulation J Affect Disord 162:134–41.
Veerman SRT, Schulte PFJ, de Haan L. (2017) Treatment for negative symptoms in schizophrenia: a comprehensive review Drugs 77:1423–1459.
Viechtbauer W. (2010) Conducting meta-analysis in R with metafor package J Stat Softw.
Young RC, Biggs JT, Ziegler VE, Meyer DA. (1978) A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 133:429–435.
Zimmerman M, Posternak MA, Chelminski I. (2004) Defining remission on the Montgomery-Asberg depression rating scale J Clin Psychiatry 65:163–168.